Evidence map›Paper›PMID 33432200›Full record

ReviewNature metabolism2021

Metabolic Messengers: glucagon-like peptide 1.

Fiona M Gribble, Frank Reimann

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 2 pooled it
18.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 2 syntheses or guidelines pooled it, 180 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. L-cell-specificActa pharmaceutica Sinica. B · 2026
    Article
  8. Article
  9. The Role and Mechanism of Incretins in Gynaecologic Diseases.Endocrinology, diabetes & metabolism · 2026
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Fiona M GribbleWellcome Trust MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. fmg23@cam.ac.uk.ORCID http://orcid.org/0000-0002-4232-2898
Frank ReimannWellcome Trust MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. fr222@cam.ac.uk.ORCID http://orcid.org/0000-0001-9399-6377
Wellcome/MRC Institute of Metabolic Science · GB

Funding

Medical Research Council MC_UU_00014/3Medical Research Council MC_UU_12012/3Wellcome Trust 106262/Z/14/ZWellcome Trust 106263/Z/14/Z
6 · The paper itself

Abstract

Glucagon like peptide-1 (GLP-1), a peptide hormone from the intestinal tract, plays a central role in the coordination of postprandial glucose homeostasis through actions on insulin secretion, food intake and gut motility. GLP-1 forms the basis for a variety of current drugs for the treatment of type 2 diabetes and obesity, as well as new agents currently being developed. Here, we provide a concise overview of the core physiology of GLP-1 secretion and action, and the role of the peptide in human health, disease and therapeutics.

Indexed as

AnimalsGastrointestinal HormonesGlucagon-Like Peptide 1HumansGastrointestinal HormonesGlucagon-Like Peptide 1

Identifiers

PMID33432200
OpenAlexW3119033633

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.